Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients
Eun Young Choi, Hee Ho Park, Hyelim Kim, Hong Nam Kim, In‐Young Kim, Soyoung Jeon, Wantae Kim, Jong‐Sup Bae, Wonhwa Lee
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread globally, resulting in declaration of pandemic emergency [1]. COVID-19 patients suffer from various symptoms of infection, including pneumonia, acute respiratory distress syndrome (ARDS) and sepsis. Some known antiviral drugs, including remdesivir, have been proposed as effective agents for the treatment of SARS-CoV-2 infection [2, 3]. Along with the development of potential therapeutics, there is urgency to mitigate the transmission and economic crisis of SARS-CoV-2 via identification of biomarkers that can rapidly indicate the severity of the disease in infected patients. Wnt ligands are secreted glycoproteins and their downstream signalling plays a pivotal role in embryonic development and tissue homeostasis. Wnt5a/Wnt11 can be used as potential ARDS biomarkers for SARS-CoV-2 patients <https://bit.ly/3lxEGRA> We thank the patients who participated in this study.